COHERUS BIOSCIENCES I

Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022

05 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma

01 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences to Report Third Quarter 2021 Financial Results on November 8th

29 Oct 2021 16:11:55 By Nasdaq GlobeNewswire

Coherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson

11 Oct 2021 08:30:00 By Nasdaq GlobeNewswire

Coherus Announces Positive Results of UDENYCA® On-Body Injector Clinical Trial

05 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

Positive Results of Clinical Trial Comparing Coherus’ Ranibizumab Biosimilar Candidate CHS-201 to Reference Product Lucentis® (Ranibizumab) in the Treatment of Neovascular (Wet) Age-Related Macular Degeneration (nAMD) Presented at Retina Society Annual Scientific Meeting

04 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

Coherus Announces BLA Filing for Lucentis® (ranibizumab) Biosimilar Candidate Accepted by FDA for Review

01 Oct 2021 13:09:14 By Nasdaq GlobeNewswire

Coherus BioSciences Mourns the Passing of Board Member Dr. Samuel Nussbaum

29 Sep 2021 16:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

24 Sep 2021 16:15:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma

16 Sep 2021 18:28:22 By Nasdaq GlobeNewswire